Dr. Richa Chandra is physician scientist and serves as the Clinical Development Head for Global Health Programs at Novartis, overseeing development of innovative medicines for Malaria, Sickle Cell Disease, Leishmaniasis, Viral, and Neglected Tropical Diseases. With over 25 years of comprehensive experience in vaccine and drug development across the pharmaceutical industry (Novartis and Pfizer) and academia, she has contributed to all phases of clinical research globally with special focus on low-and middle-income countries. Dr. Chandra has represented the pharmaceutical industry on the FDA’s Advisory Committee for anti-infective drugs since 2019.
Prior to her tenure at Novartis, she led Pfizer’s Malaria Development Program for adults, children, and pregnant women, and previously held the role of Global Head of Translational Medicine for Infectious Diseases. Richa started her pharmaceutical career in Pfizer India and was responsible for establishing Pfizer’s pioneering International Clinical Research Operations – making Pfizer the first sponsor to conduct clinical trials as per ICH-GCP standards in India for submission to stringent regulatory authorities. Before entering the pharmaceutical industry, Dr. Chandra was a faculty member at Seth GS Medical College and KEM Hospital in Mumbai.
Panel discussion
